Quarterly report pursuant to Section 13 or 15(d)

Investment in Saneron CCEL Therapeutics, Inc. (''Saneron'') - Additional Information (Detail)

v2.4.0.8
Investment in Saneron CCEL Therapeutics, Inc. (''Saneron'') - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2014
Nov. 30, 2013
Aug. 31, 2014
Accumulated Deficit [Member]
Aug. 31, 2014
Treasury Stock [Member]
Aug. 31, 2014
Saneron [Member]
Aug. 31, 2014
Saneron [Member]
Installment
Nov. 30, 2013
Saneron [Member]
Aug. 31, 2014
Saneron [Member]
Valuation Allowance Investment [Member]
Aug. 31, 2014
Saneron [Member]
Valuation Allowance Investment [Member]
Aug. 31, 2014
Saneron [Member]
Common Stock and Warrant Awards [Member]
Aug. 31, 2013
Saneron [Member]
Common Stock and Warrant Awards [Member]
Aug. 31, 2014
Saneron [Member]
Common Stock and Warrant Awards [Member]
Aug. 31, 2013
Saneron [Member]
Common Stock and Warrant Awards [Member]
Aug. 31, 2014
Saneron [Member]
Initial Loan [Member]
Installment
Aug. 31, 2014
Saneron [Member]
Additional Loan [Member]
Installment
Investments In Affiliates [Line Items]                              
Ownership interest         33.00% 33.00% 34.00%                
Equity method investment $ 758,764 $ 684,000     $ 758,764 $ 758,764 $ 684,000                
Goodwill             684,000                
Equity method investment, other than temporary impairment loss           0 0                
Goodwill impairment loss           0 0                
Loan Saneron in quarterly payments an aggregate amount         300,000 300,000                  
Initial loan amount         150,000 150,000                 150,000
Additional quarterly payments           4               4 4
Quarterly installments per quarter                           37,500 37,500
Date of maturity           5 years                  
Quarterly installments per quarter           37,500                  
Equity in losses         53,000 242,000       8,500 39,000 86,000 115,000    
Valuation allowances on investment               37,500 150,000            
Common shares repurchased         93,800                    
Common shares per share value         $ 2.60 $ 2.60                  
Common shares sold by Saneron         56,300                    
Reclassification from treasury stock to accumulated deficit.     $ (400,000) $ 400,000